STOCK TITAN
  1. Home
  2. News
  3. BTTX

BETTER THERAPEUTICS INC - BTTX STOCK NEWS

Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.

Better Therapeutics Inc. (BTTX) is at the forefront of developing prescription digital therapeutics aimed at treating chronic diseases. The company, formerly known as Farewell, leverages a unique combination of software, human coaching enhanced by artificial intelligence, and advanced analytics to address the underlying behaviors causing most chronic conditions. This innovative approach offers scalable solutions capable of impacting millions of lives.

Better Therapeutics' digital therapeutics are grounded in solid evidence and align with existing clinical treatment guidelines. They can be integrated with other interventions or used independently, providing flexible and effective treatment options. The company's non-drug solutions are pivotal in reducing the health and financial burdens of chronic diseases on individuals, healthcare payers, and the broader healthcare system.

Recent achievements include significant advancements in their AI-driven coaching systems and the successful integration of their digital therapeutics into various healthcare settings. Better Therapeutics is continually expanding its partnerships and collaborations to further enhance the reach and effectiveness of its products.

The company's financial health reflects steady growth, driven by its innovative products and expanding market presence. Better Therapeutics remains committed to advancing its mission of improving chronic disease management through cutting-edge digital solutions.

News

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Rhea-AI Summary
Better Therapeutics (NASDAQ: BTTX) receives Frost & Sullivan's 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry for its AspyreRx app. The award recognizes the company's unique architecture for scalability and potential expansion to other cardiometabolic conditions. AspyreRx is the first prescription-only digital therapeutic for type 2 diabetes, with FDA authorization for commercial use in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
News

Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced its commercial launch. The company also reported Q3 financial results and provided updates on key milestones. AspyreRx offers a clinically proven, convenient, and cost-effective treatment option for type 2 diabetes. The company is focused on demonstrating commercial traction and securing payer coverage. Third quarter business highlights include FDA authorization, completion of an evidence program, new patent issuance, commercial launch, study results publication, and data showing superior clinical outcomes. The company also raised additional capital and expects to achieve upcoming milestones related to payer coverage, FDA designation, business development partnership, and financial strengthening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
earnings
-
News

Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) to release Q3 2023 financial results and host conference call for a business update on November 9, 2023. Register for the call at the provided link. Access codes will be provided upon registration. Webcast link also available for live viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
earnings
News

Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference

Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) will showcase its prescription digital therapeutic, AspyreRx, at the American College of Lifestyle Medicine's 2023 Annual Conference. AspyreRx is a FDA-authorized treatment for adults with type 2 diabetes, offering a proprietary form of cognitive behavioral therapy. The company will also host an education session to present clinical data and the treatment's mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
conferences
-
News

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

Rhea-AI Summary
Better Therapeutics launches AspyreRx, the first FDA-authorized digital behavioral therapeutic device for the treatment of type 2 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.21%
Tags
none
-
News

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Rhea-AI Summary
Better Therapeutics announces positive findings from a recent subgroup analysis of AspyreRx in its pivotal trial for type 2 diabetes. The use of AspyreRx alongside standard of care, including GLP-1 receptor agonists, leads to a substantial reduction in HbA1c compared to control participants. Participants on both GLP-1 medications and AspyreRx also showed greater HbA1c reduction, weight loss, and utilized fewer medications compared to participants on GLP-1 medications without AspyreRx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
none
News

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances

Rhea-AI Summary
Better Therapeutics announces positive results from the LivVita study, showing reduction in liver fat and improved liver health with their prescription digital therapeutics. The company plans to request Breakthrough Device Designation from the FDA by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.64%
Tags
none
-
News

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Rhea-AI Summary
Better Therapeutics completes enrollment of 1,000 participants across two studies to evaluate long-term effectiveness of AspyreRxTM for type 2 diabetes treatment. Initial 6-month data expected by end of 2023. Commercial launch planned for Q4 this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
-
News

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Rhea-AI Summary
Better Therapeutics reports Q2 2023 financial results and progress towards key milestones. FDA authorization received for AspyreRxTM to treat type 2 diabetes. Commercial launch expected in Q4. Completed financing transactions totaling $12.5 million in net proceeds. Company sets price for AspyreRx at $750 for a 90-day script.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
earnings
News

Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023

Rhea-AI Summary
Better Therapeutics (BTTX) to Release Q2 2023 Financial Results and Host Business Update Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
earnings

FAQ

What is the current stock price of BETTER THERAPEUTICS (BTTX)?

The current stock price of BETTER THERAPEUTICS (BTTX) is $0.0001 as of September 13, 2024.

What is the market cap of BETTER THERAPEUTICS (BTTX)?

The market cap of BETTER THERAPEUTICS (BTTX) is approximately 5.5K.

What does Better Therapeutics Inc. do?

Better Therapeutics Inc. develops prescription digital therapeutics for treating chronic diseases using a blend of software, AI-enhanced human coaching, and advanced analytics.

How do Better Therapeutics' solutions work?

Their solutions target the behaviors causing chronic conditions, using evidence-based digital therapeutics that fit within clinical guidelines and can be scaled to impact millions.

What makes Better Therapeutics' approach unique?

The company combines digital therapeutics with AI-enhanced human coaching and advanced analytics, offering scalable non-drug treatment options for chronic diseases.

Can Better Therapeutics' products be used with other treatments?

Yes, their digital therapeutics can be used independently or integrated with other clinical interventions.

What recent achievements has Better Therapeutics made?

They have advanced their AI-driven coaching systems and successfully integrated their therapeutics into various healthcare settings, expanding their impact.

How does Better Therapeutics impact healthcare costs?

Their non-drug treatments aim to reduce the health and cost burdens of chronic diseases on individuals and healthcare systems.

What evidence supports Better Therapeutics' products?

Their digital therapeutics are based on well-established evidence and align with current clinical treatment guidelines, ensuring efficacy and reliability.

Who can benefit from Better Therapeutics' solutions?

Individuals with chronic diseases, healthcare providers, and payers can benefit from their innovative, scalable digital therapeutics.

What is the financial condition of Better Therapeutics?

The company shows steady growth driven by its innovative products and expanding market presence, reflecting a healthy financial outlook.

What is the mission of Better Therapeutics?

Their mission is to improve chronic disease management and reduce healthcare costs through advanced digital therapeutics.

Stock BTTX logo
BETTER THERAPEUTICS INC

Nasdaq:BTTX

BTTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BTTX Stock Data

5.45k
25.82M
48.23%
0.01%
3.9%
Biotechnology
Healthcare
Link
United States of America
San Francisco